The landmark approval of @Biogen’s Aduhelm intensifies the need for early detection and screening in Alzheimer’s disease, and highlights the importance of stratification in clinical trials. Vivid Genomics is addressing both of these issues.
Vivid Genomics
@VGenomics
Using AI, genomics, and dementia biology to develop non-invasive tests. Helping pharma companies identify patient variation in clinical trials.
194 Following 205 Followers 131 Posts
Latest posts 5
We're presenting this week at @CTADconference virtual poster hall. Rate of decline affects trials in both pre-screen trial populations and among enrolled individuals; broad genetics improves prediction in both. Posters LP13 & P65 from Nov 4-7 at 1pm ET.
#CTAD2020 #ENDALZ
#CTAD2020 #ENDALZ
When #dementia clinical trials have placebo arms that do not decline, it's hard to see a drug effect. Join us at the #ISCTM2020 poster session tomorrow at 11:50am PT as we present the value of genome wide variants beyond APOE to improve predictive models of cognitive decline.
Our founder & CEO Julie Collens was featured on the @TacosandTechPod with @NealBloom! Tune in to hear about what brought her to San Diego, her early career, and her entrepreneurial journey. 🌮 https://t.co/eUIGQt5OzJ
We're excited to have been selected again as one of San Diego's "Cool Companies"! @sdvg